Further insights into the pathogenesis of primary hyperparathyroidism: A nested case-control study

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 1, 2013, Pages 87-96

  Rejnmark, Lars ^a   Amstrup, Anne Kristine ^a   Mollerup, Charlotte L ^b   Heickendorff, Lene ^a   Mosekilde, Leif ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYERGOCALCIFEROL; CALCIUM; PARATHYROID HORMONE;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CANCER SURGERY; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; HUMAN; HYPERCALCEMIA; MAJOR CLINICAL STUDY; MALE; PARATHYROID ADENOMA; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HYPERPLASIA; PARATHYROIDECTOMY; PATHOPHYSIOLOGY; PREDICTION; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; VITAMIN BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ASYMPTOMATIC DISEASES; CALCIUM; CASE-CONTROL STUDIES; COHORT STUDIES; DENMARK; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERPARATHYROIDISM, PRIMARY; MALE; MIDDLE AGED; PARATHYROID HORMONE; PREDICTIVE VALUE OF TESTS; VITAMIN D;

EID: 84872070368     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-2499     Document Type: Article

References (37)

1. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP 1999 A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 341:1249-1255
2. Bollerslev J, Jansson S, Mollerup CL, Nordenström J, Lundgren E, Torring O, Varhaug JE, Baranowski M, Aanderud S, Franco C, Freyschuss B, Isaksen GA, Ueland T, Rosen T 2007 Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. J Clin Endocrinol Metab 92:1687-1692
3. Mosekilde L 2008 Primary hyperparathyroidism and the skeleton. Clin Endocrinol (Oxf) 69:1-19
4. Jones G, Sambrook PN 1994 Drug-induced disorders of bone metabolism. Incidence, management and avoidance. Drug Saf 10:480- 489
5. Saliba W, Lavi I, Rennert HS, Rennert G 2012 Vitamin D status in primary hyperparathyroidism. Eur J Intern Med 23:88-92
6. Moosgaard B, Vestergaard P, Heickendorff L, Melsen F, Christiansen P, Mosekilde L 2005 Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism. Clin Endocrinol (Oxf) 63:506-513
7. Silverberg SJ, Shane E, Dempster DW, Bilezikian JP 1999 The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. Am J Med 107:561-567
8. Rolighed L, Bollerslev J, Mosekilde L 2011 Vitamin D treatment in primary hyperparathyroidism. Curr Drug Saf 6:100-107
9. Shlapack MA, Rizvi AA 2012 Normocalcemic primary hyperparathyroidism- characteristics and clinical significance of an emerging entity. Am J Med Sci 343:163-166
10. Lundgren E, Rastad J, Thrufjell E, Akerström G, Ljunghall S 1997 Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery 121:287-294
11. Lundgren E, Hagström EG, Lundin J, Winnerbäck K, Roos J, Ljunghall S, Rastad J 2002 Primary hyperparathyroidism revisited in menopausal women with serum calcium in the upper normal range at population-based screening 8 years ago. World J Surg 26:931-936
12. Silverberg SJ, Bilezikian JP 2003 "Incipient" primary hyperparathyroidism: a "forme fruste" of an old disease. J Clin Endocrinol Metab 88:5348-5352
13. Lowe H, McMahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ 2007 Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab 92:3001-3005
14. Silverberg SJ, Lewiecki EM, Mosekilde L, Peacock M, Rubin MR 2009 Presentation of asymptomatic primary hyperparathyroidism: proceedings of the Third International Workshop. J Clin Endocrinol Metab 94:351-365
15. Eastell R, Arnold A, Brandi ML, Brown EM, D'Amour P, Hanley DA, Rao DS, Rubin MR, Goltzman D, Silverberg SJ, Marx SJ, Peacock M, Mosekilde L, Bouillon R, Lewiecki EM 2009 Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Third International Workshop. J Clin Endocrinol Metab 94:340-350
16. Souberbielle JC, Cormier C, Kindermans C, Gao P, Cantor T, Forette F, Baulieu EE 2001 Vitamin D status and redefining serum parathyroid hormone reference range in the elderly. J Clin Endocrinol Metab 86:3086-3090
17. Souberbielle JC, Bienaime F, Cavalier E, Cormier C 2012 Vitamin D and primary hyperparathyroidism (PHPT). Ann Endocrinol (Paris) 73:165-169
18. Mosekilde L, Hermann AP, Beck-Nielsen H, Charles P, Nielsen SP, Sorensen OH 1999 The Danish Osteoporosis Prevention Study (DOPS): project design and inclusion of 2000 normal perimenopausal women. Maturitas 31:207-219
19. Tjønneland A, Olsen A, Boll K, Stripp C, Christensen J, Engholm G, Overvad K 2007 Study design, exposure variables, and socioeconomic determinants of participation in diet, cancer and health: a population-based prospective cohort study of 57,053 men and women in Denmark. Scand J Public Health 35:432-441
20. Nordestgaard BG, Benn M, Schnohr P, Tybjærg-Hansen A 2007 Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 298:299-308
21. Andersen TF, Madsen M, Jørgensen J, Mellemkjoer L, Olsen JH 1999 The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 46:263-268
22. Maunsell Z, Wright DJ, Rainbow SJ 2005 Routine isotope-dilution liquid chromatography-tandem mass spectrometry assay for simultaneous measurement of the 25-hydroxy metabolites of vitamins D2 and D3. Clin Chem 51:1683-1690
23. Højskov CS, Heickendorff L, Møller HJ 2010 High-throughput liquid-liquid extraction and LCMSMS assay for determination of circulating 25(OH) vitamin D3 and D2 in the routine clinical laboratory. Clin Chim Acta 411:114-116
24. Lund B, Sørensen OH 1979 Measurement of 25-hydroxyvitamin D in serum and its relation to sunshine, age and vitamin D intake in the Danish population. Scand J Clin Lab Invest 39:23-30
25. Gault MH, Longerich LL, Harnett JD, Wesolowski C 1992 Predicting glomerular function from adjusted serum creatinine. Nephron 62:249-256
26. Lips P 2001 Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 22:477-501
27. Rao DS, Agarwal G, Talpos GB, Phillips ER, Bandeira F, Mishra SK, Mithal A 2002 Role of vitamin D and calcium nutrition in disease expression and parathyroid tumor growth in primary hyperparathyroidism: a global perspective. J Bone Miner Res 17(Suppl 2):N75-N80
28. Mosekilde L 2005 Vitamin D and the elderly. Clin Endocrinol (Oxf) 62:265-281
29. Rejnmark L, Vestergaard P, Heickendorff L, Mosekilde L 2011 Determinants of plasma PTH and their implication for defining a reference interval. Clin Endocrinol (Oxf) 74:37-43
30. Christensen SE, Nissen PH, Vestergaard P, Heickendorff L, Rejnmark L, Brixen K, Mosekilde L 2008 Plasma 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and parathyroid hormone in familial hypocalciuric hypercalcemia and primary hyperparathyroidism. Eur J Endocrinol 159:719-727
31. Bilezikian JP, Silverberg SJ 2010 Normocalcemic primary hyperparathyroidism. Arq Bras Endocrinol Metabol 54:106-109
32. Al-Azem H, Khan A 2011 Primary hyperparathyroidism. CMAJ 183:E685-E689
33. Amstrup AK, Rejnmark L, Vestergaard P, Sikjaer T, Rolighed L, Heickendorff L, Mosekilde L 2011 Vitamin D status, physical performance and body mass in patients surgically cured for primary hyperparathyroidism compared with healthy controls - a cross-sectional study. Clin Endocrinol (Oxf) 74:130-136
34. Lloyd HM 1968 Primary hyperparathyroidism: an analysis of the role of the parathyroid tumor. Medicine (Baltimore) 47:53-71
35. Rejnmark L, Vestergaard P, Brot C, Mosekilde L 2011 Increased fracture risk in normocalcemic postmenopausal women with high parathyroid hormone levels: a 16-year follow-up study. Calcif Tissue Int 88:238-245
36. Monchik JM, Gorgun E 2004 Normocalcemic hyperparathyroidism in patients with osteoporosis. Surgery 136:1242-1246
37. Peiris AN, Youssef D, Grant WB 2012 Secondary hyperparathyroidism: benign bystander or culpable contributor to adverse health outcomes? South Med J 105:36-42